Liquidia Corp is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare and serious diseases

Utilizing its proprietary PRINT technology, Liquidia designs and manufactures novel drug formulations that enhance the delivery and effectiveness of established medications. The company is dedicated to addressing unmet medical needs by advancing its product pipeline, which targets various conditions, including pulmonary and cardiovascular diseases. Through its commitment to research and development, Liquidia aims to improve the quality of life for patients through more effective therapeutic options.